CRISPR Therapeutics' CTX310 lowers triglycerides 63% in Phase 1b trial

By Public Technologies
  • CRISPR Therapeutics presented Phase 1b results for CTX310 in severe hypertriglyceridemia today at the American Heart Association Scientific Sessions 2026.
  • The investigational gene-editing therapy substantially reduced triglycerides following a single treatment, with reductions maintained during longer follow-up.
  • Treatment was well tolerated, with no treatment-related serious adverse events or clinically relevant liver enzyme elevations.
  • The FDA recently granted CTX310 Regenerative Medicine Advanced Therapy designations for severe hypertriglyceridemia and elevated LDL cholesterol; Phase 1b trials remain ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090916PRIMZONEFULLFEED9873094) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk